Presentations by Björn Nashan

• Mon-14 from 14:30 - 15:15 in room Channel 8
  Oral Abstracts Session — Established IS
  Correlation of trough level compliance and protection of renal function after liver transplantation – A post-hoc analysis from the Hephaistos study
• Tue-15 from 23:30 - 00:15 in room Channel 8
  Oral Abstracts Session — Cell and Novel Therapies
  Phase 2 study design evaluating efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-CD40 monoclonal antibody CFZ533 (iscalimab) in de novo liver transplant recipients: The CONTRAIL I study
• from in room E-Poster Hall
  Poster Session — Transplant Immunosuppression
  Athena vs Hephaistos - Are discontinuation rates in multicenter studies driven by facts or attitudes?